Literature DB >> 23307265

Inhaled tiotropium to prevent postoperative cardiopulmonary complications in patients with newly diagnosed chronic obstructive pulmonary disease requiring lung cancer surgery.

Takashi Nojiri1, Masayoshi Inoue, Kazuhiro Yamamoto, Hajime Maeda, Yukiyasu Takeuchi, Tomoyuki Nakagiri, Yasushi Shintani, Masato Minami, Noriyoshi Sawabata, Meinoshin Okumura.   

Abstract

PURPOSE: A new diagnosis of chronic obstructive pulmonary disease is often made during the evaluation of patients requiring lung cancer surgery. The objective of the present study was to evaluate the clinical effects of inhaled tiotropium on the postoperative cardiopulmonary complications in patients with untreated chronic obstructive pulmonary disease requiring lung cancer surgery.
METHODS: A retrospective study involving 104 consecutive patients with moderate to severe chronic obstructive pulmonary disease who underwent a lobectomy for lung cancer at two specialized thoracic centers between April 2008 and October 2011 was performed. The results were compared between patients who did and did not receive inhaled tiotropium during the perioperative period. The primary endpoint was the incidence of postoperative cardiopulmonary complications. The postoperative white blood cell counts and C-reactive protein levels as biomarkers of inflammation were also examined.
RESULTS: The incidence of postoperative cardiopulmonary complications was significantly lower in the tiotropium group than in the control group (18 vs. 48 %, P = 0.001). Patients in the tiotropium group also showed significantly lower white blood cell counts and C-reactive protein levels postoperatively.
CONCLUSIONS: Inhaled tiotropium treatment during the perioperative period had a prophylactic effect on postoperative cardiopulmonary complications in patients with newly diagnosed chronic obstructive pulmonary disease requiring lung cancer surgery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23307265     DOI: 10.1007/s00595-012-0481-5

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  23 in total

1.  Relationship between pulmonary function and lung cancer surgical outcome.

Authors:  T Win; A Jackson; L Sharples; A M Groves; F C Wells; A J Ritchie; C M Laroche
Journal:  Eur Respir J       Date:  2005-04       Impact factor: 16.671

Review 2.  Cardiovascular risk in chronic obstructive pulmonary disease.

Authors:  John D Maclay; David A McAllister; William Macnee
Journal:  Respirology       Date:  2007-09       Impact factor: 6.424

Review 3.  Chronic obstructive pulmonary disease. Inflammation of small airways and lung parenchyma.

Authors:  M G Cosio; A Guerassimov
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

4.  Predictive value of preoperative tissue Doppler echocardiographic analysis for postoperative atrial fibrillation after pulmonary resection for lung cancer.

Authors:  Takashi Nojiri; Hajime Maeda; Yukiyasu Takeuchi; Yasunobu Funakoshi; Ryoji Maekura; Kazuhiro Yamamoto; Meinoshin Okumura
Journal:  J Thorac Cardiovasc Surg       Date:  2010-08-09       Impact factor: 5.209

5.  Cardiovascular safety of tiotropium in patients with COPD.

Authors:  Bartolome Celli; Marc Decramer; Inge Leimer; Ulrich Vogel; Steven Kesten; Donald P Tashkin
Journal:  Chest       Date:  2009-07-10       Impact factor: 9.410

6.  Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk.

Authors:  N L Mills; J J Miller; A Anand; S D Robinson; G A Frazer; D Anderson; L Breen; I B Wilkinson; C M McEniery; K Donaldson; D E Newby; W Macnee
Journal:  Thorax       Date:  2007-11-16       Impact factor: 9.139

7.  Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD.

Authors:  Seiichi Kobayashi; Satoshi Suzuki; Hiromichi Niikawa; Takafumi Sugawara; Masaru Yanai
Journal:  Respirology       Date:  2009-05-19       Impact factor: 6.424

8.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Authors:  Donald P Tashkin; Bartolome Celli; Stephen Senn; Deborah Burkhart; Steven Kesten; Shailendra Menjoge; Marc Decramer
Journal:  N Engl J Med       Date:  2008-10-05       Impact factor: 91.245

9.  Risks for atrial fibrillation and congestive heart failure in patients >/=65 years of age with abnormal left ventricular diastolic relaxation.

Authors:  Teresa S M Tsang; Marion E Barnes; Bernard J Gersh; Kent R Bailey; James B Seward
Journal:  Am J Cardiol       Date:  2004-01-01       Impact factor: 2.778

10.  COPD prevalence is increased in lung cancer, independent of age, sex and smoking history.

Authors:  R P Young; R J Hopkins; T Christmas; P N Black; P Metcalf; G D Gamble
Journal:  Eur Respir J       Date:  2009-02-05       Impact factor: 16.671

View more
  13 in total

Review 1.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

2.  Is left upper lobectomy for lung cancer a risk factor for cerebral infarction?

Authors:  Takayoshi Yamamoto; Hidemi Suzuki; Kaoru Nagato; Takahiro Nakajima; Takekazu Iwata; Shigetoshi Yoshida; Ichiro Yoshino
Journal:  Surg Today       Date:  2015-08-14       Impact factor: 2.549

Review 3.  Modifiable risk factors for patients undergoing lung cancer surgery and their optimization: a review.

Authors:  Sylvain Gagné; Daniel I McIsaac
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

4.  Airflow Limitation Predicts Postoperative Pneumonia after Esophagectomy.

Authors:  Suguru Maruyama; Akihiko Okamura; Naoki Ishizuka; Yasukazu Kanie; Kei Sakamoto; Daisuke Fujiwara; Jun Kanamori; Yu Imamura; Masayuki Watanabe
Journal:  World J Surg       Date:  2021-05-03       Impact factor: 3.352

Review 5.  Risk factors predictive of atrial fibrillation after lung cancer surgery.

Authors:  Takekazu Iwata; Kaoru Nagato; Takahiro Nakajima; Hidemi Suzuki; Shigetoshi Yoshida; Ichiro Yoshino
Journal:  Surg Today       Date:  2015-10-15       Impact factor: 2.549

6.  Long-acting muscarinic antagonist and long-acting β2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery.

Authors:  Takashi Makino; Hajime Otsuka; Yoshinobu Hata; Satoshi Koezuka; Yoko Azuma; Kazutoshi Isobe; Keishi Sugino; Satoru Ebihara; Sakae Homma; Akira Iyoda
Journal:  Mol Clin Oncol       Date:  2018-03-26

7.  Evaluation of emphysema using three-dimensional computed tomography: association with postoperative complications in lung cancer patients.

Authors:  Kenichi Kawakami; Shingo Iwano; Naozumi Hashimoto; Yoshinori Hasegawa; Shinji Naganawa
Journal:  Nagoya J Med Sci       Date:  2015-02       Impact factor: 1.131

8.  Prophylactic penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients: study protocol of a randomized controlled trial.

Authors:  Ting Yan; Xin-Quan Liang; Tong Wang; Wei-Ou Li; Hui-Juan Li; Sai-Nan Zhu; Dong-Xin Wang
Journal:  Trials       Date:  2017-11-28       Impact factor: 2.279

9.  Long acting β2-adrenocepter agonists are not associated with atrial arrhythmias after pulmonary resection.

Authors:  Keiji Yamanashi; Satoshi Marumo; Ryota Sumitomo; Tsuyoshi Shoji; Motonari Fukui; Toshiro Katayama; Cheng-Long Huang
Journal:  J Cardiothorac Surg       Date:  2017-05-19       Impact factor: 1.637

10.  Survival significance of coexisting chronic obstructive pulmonary disease in patients with early lung cancer after curative surgery.

Authors:  Hisashi Saji; Tomoyuki Miyazawa; Hiroki Sakai; Yusuke Kimura; Masataka Tsuda; Yoichi Wakiyama; Hideki Marushima; Koji Kojima; Haruhiko Nakamura
Journal:  Thorac Cancer       Date:  2017-10-04       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.